AnaptysBio opened lower at $48.23, compared with its previous close of $48.77. In the last trading session, the stock traded between $47.68 and $48.87. It showed a downward intraday trend.
Return calculator
Time Period
An investment of $100 made 5 years ago in AnaptysBio is now worth
$ 143.63
Giving a profit of
$ 43.63 (43.63%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 6 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
$-1.00 (-2.05%)
Day High
$48.87
Day Low
$47.68
Day Open
$48.23
Prev Close
$48.77
Volume
1,82,561
1W Return
0.59%
1M Return
3.79%
3M Return
-17.40%
6M Return
-29.67%
1Y Return
42.35%
Fundamentals
Market Cap ($ Mn)
1,428
PE Ratio
-
PB Ratio
128.18
PEG Ratio
-
ROE
-97.37%
ROCE
15.18%
EPS (TTM)
$1.80
Investment Returns
1 Week
0.59%
1 Month
3.79%
3 Months
-17.40%
6 Months
-29.67%
9 Months
-13.54%
Financials
Quarterly
All values in $ Mn
30.0
Sep 24
43.1
Dec 24
27.8
Mar 25
22.3
Jun 25
76.3
Sep 25
108.2
Dec 25
Updates
13Nov
AnaptysBio Q3 Results: EPS $0.11 misses estimate, sales fall 60%
AnaptysBio Q3 EPS of $0.11 missed the $1.58 consensus estimate by 93.04%. Quarterly sales fell 60.33% YoY to $30.274 million, missing estimates by 8.78%. EPS declined 78.85% from $0.52 in the same period last year.
Today
22Sep
AnaptysBio Q2FY26 Results: Adj. EPS beats est, sales up 23%
Adjusted EPS of $(0.11) beat consensus estimate of $(0.46) by 76%. Q2FY26 sales rose 23% YoY to $27.5 million, beating $21.7M estimate. Net income surged to $177.3 million driven by $181.5 million tax benefit. G&A expenses tripled to $16.0 million due to legal costs and separation.
1mo ago
2Sep
AnaptysBio CFO to present at H.C. Wainwright investment conference
CFO Chris Murphy to present at H.C. Wainwright conference on Sept 15, 2026. Presentation starts at 3:30 pm ET with live webcast available. Anaptys manages royalty collaborations for Jemperli and imsidolimab.
2mo ago
10Jun
HC Wainwright assumes AnaptysBio at Buy, sets $95 target
HC Wainwright & Co. analyst Joseph Pantginis assumed coverage of AnaptysBio with a Buy rating and a price target of $95.
